ymal stem cells (MSCs) for various diseases. There have been no preclinical reports, however, to support the use of pulp stem cells as a potential treatment for pulpitis in clinical trials,” Dr. Nakashima said. “We also knew that previous studies involving the spinal cord show that combining G-CSF with stem cells derived from other types of tissues, bone marrow stromal cells, neuronal stem cells and amniotic fluid stem cells had several benefits. So we reasoned that G-CSF might positively impact the pulp stem cells, too.”
When they examined the results, which included comparing the G-CSF treated cells to a control group of non-treated cells, they found the cells did indeed regenerate the pulp tissue and completely filled in the dogs’ root canals.
“We also noted that the pulp stem cells treated with G-CSF yielded a significantly larger amount of regenerated dentin-pulp complex than those without it,” Dr. Nakashima observed. “Also noteworthy was the reduced number of inflammatory cells, the decrease in cell death and the significant increase in neurite outgrowth (the projections that transfer a cell’s impulses compared to those without G-CSF). Furthermore, there was no evidence of toxicity or adverse events.”
Based on these preclinical results of efficacy and safety, a clinical trial of pulp regeneration has already been initiated with the permission of the Japanese Ministry of Health, Labor and Welfare, she added.
“This first preclinical demonstration of the efficacy and safety after transplantation of clinical-grade pulp stem cells together with G-CSF for dentin-pulp regeneration is very encouraging,” said Anthony Atala, M.D., Editor of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine.
The full article, “A novel combinatorial therapy with pulp stem cells and G-CSF for total pulp regeneration,” can be accessed at
Page: 1 2 3 Related biology technology :1
Copyright©2012 Vocus, Inc.
All rights reserved
. Valkee and University of Oulu Publish the First Clinical Trial on Bright Light Therapy Channeled via ear Canals in Seasonal Depression2
. Prolongs Large Scale Manufacturing of Sickle Cell Product to be Headed by Industry Veteran3
. Adult Acne Treatment Explains a New Upcoming Study that may Change the Acne Treatment Industry4
. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology5
. Endpoint Based Protocol Development: A Central Laboratory Perspective + Microbiology Case Study, New Life Science Webinar Hosted by Xtalks6
. AbbVie Presents Results from Phase I Study of Investigational Oncology Compound ABT-199 at American Society of Clinical Oncology Annual Meeting7
. New study identifies the role of a key growth factor in promoting formation of hair follicles and suggests a new therapeutic approach to treat baldness8
. Primary Progression-Free Survival Endpoint Met in Phase III Study of Nintedanib Plus Docetaxel in Second-Line Advanced NSCLC9
. Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology10
. Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)11
. Study led by GW professor provides better understanding of waters freezing behavior at nanoscale